Skip to content

The application and mechanism of non-steroidal anti-inflammatory drugs in the treatment of pediatric Gitelman syndrome patients

The application and mechanism of non-steroidal anti-inflammatory drugs in the treatment of pediatric Gitelman syndrome patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038234
Enrollment
Unknown
Registered
2020-09-15
Start date
2020-10-10
Completion date
Unknown
Last updated
2020-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gitelman syndrome

Interventions

GS:Indomecine
Control group:nil

Sponsors

Capital Institute of Pediatrics
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
2 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. According to the medical history, the patients with insufficient dietary potassium intake, digestive tract potassium loss or hypokalemia secondary to diuretics were excluded; 2. Patients with renal potassium loss: when serum potassium is less than 3.0 mmol / L, 24-hour urine potassium is more than 20 mmol; 3. When serum potassium was less than 3.5 mmol/L, 24-hour urine potassium was more than 25 mmol; 4. Patients with normal or low blood pressure; 5. Patients with metabolic alkalosis.

Exclusion criteria

Exclusion criteria: Nil

Design outcomes

Primary

MeasureTime frame
serum K;

Countries

China

Contacts

Public ContactPeng Xiaoyan

Capital Institute of Pediatrics

pengxy2013xy@163.com+86 1085695054

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026